Healius Limited has been placed in a trading halt effective from 24 September 2026, following a request from the company pending the release of a material announcement regarding the sale process for its Agilex Biolabs division. The trading halt, requested pursuant to ASX Listing Rule 17.1, will remain in place until either the announcement is released to the market or trading recommences on Monday, 28 September 2026, whichever occurs first. This timeline provides Healius with approximately four business days to prepare and formally release its announcement to the market.
Trading halts serve an important function in maintaining market integrity by preventing trading in securities while material information is being prepared and released to investors. By pausing share trading, the ASX ensures that all market participants receive information simultaneously and that trading resumes only once the market has had time to absorb the news. The halt is a mechanism that protects investors from making trading decisions based on incomplete or stale information during periods when material corporate developments are imminent.
Agilex Biolabs represents a significant asset within the Healius portfolio, and any decision regarding its sale would constitute a material corporate action warranting immediate market disclosure. The pathology business has been an integral part of Healius’s operations, generating revenue streams across a network of laboratories and collection centres. A divestment of this scale would meaningfully affect the company’s financial profile, revenue generation capacity, and strategic positioning within the wider healthcare sector.
A sale of Agilex Biolabs could have substantial implications for Healius shareholders and the direction of the company. The transaction may yield proceeds that could be deployed toward debt reduction, capital returns to shareholders, strategic acquisitions, or reinvestment in other areas of the Healius business. Alternatively, the sale might represent a deliberate pivot toward the company’s core operations or a strategic response to market conditions and competitive pressures affecting the pathology sector.
The valuation multiple achieved for Agilex Biolabs will be a key indicator of the asset’s standalone value and how the market views pathology sector prospects. Investors will also closely examine how Healius intends to deploy the sale proceeds and what impact the transaction will have on debt levels, earnings per share accretion or dilution, and the company’s capital management strategy going forward.
Investors should prepare to closely examine the upcoming announcement for specific details on sale terms, buyer identity, implied valuation, expected completion timing, and any impact on Healius’s earnings guidance or strategic direction. The ability to assess whether the transaction enhances or diminishes shareholder value will depend critically on these specifics. This announcement is classified as price sensitive by the ASX and flagged as material to the market.
View the full ASX announcement (PDF)
About Healius Limited (ASX: HLS)
Healius Limited is Australia’s second-largest pathology provider, operating a network of pathology laboratories, diagnostic imaging centres, and day hospitals across the country. The company operates through Pathology and Imaging segments, providing medical laboratory services and diagnostic imaging services to patients and healthcare providers. Healius maintains around 2,000 collection sites and nearly 100 pathology laboratories throughout Australia.
If you would like to discuss this announcement, request a callback or call us on 1300 889 603.
